The Latest Breaking News from Boston Scientific Corporation

The Food and Drug Administration (FDA) said on Wednesday it is monitoring a potential safety issue involving Boston Scientific Corporation’s (NYSE:BSX) ENDOTAK RELIANCE defibrillation leads, following a letter from the company alerting healthcare providers of possible reduced shock efficacy.

Boston Scientific has recently outpaced the broader healthcare sector, with analysts maintaining a highly bullish outlook on its future performance.

MedTech’s bright future is fueled by rapid tech advancements and increasing demand for medical devices, implants, and precision treatments, driven by an aging population and rising global disease rates. Given this backdrop, adding strong MedTech stocks like Boston Scientific (BSX), Stryker (SYK), and Abbott (ABT) to one’s portfolio could be…

Even though 2024 kicked off strong, recent macroeconomic uncertainties highlight the need for resilient investments. These three “safe haven” stocks are worth considering for hedging against the market downswings.

Coupled with the macroeconomic headwinds, the U.S. debt default crisis and consequent recessionary fears have triggered market volatility. Against this backdrop, quality growth stocks Boston Scientific (BSX), Cardinal Health (CAH), Cidara Therapeutics (CDTX), and Geospace Technologies (GEOS) could be solid buys now. Read on….

Boston Scientific Corporation (NYSE:BSX) has agreed to purchase Synergy Innovation Co Ltd's majority stake (~64%) of M.I.Tech Co Ltd, a publicly-traded Korean manufacturer, and distributor of medical devices for endoscopic and urologic procedures.  The deal is valued at KRW 14,500 per share, representing KRW 291.2 billion or approximately $230 million. M.I.Tech offers HANAROSTENT technology, a…